These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 14760887)

  • 1. The potentiating effect of ribavirin on interferon in the treatment of hepatitis C: lack of evidence for ribavirin-induced viral mutagenesis.
    Schinkel J; de Jong MD; Bruning B; van Hoek B; Spaan WJ; Kroes AC
    Antivir Ther; 2003 Dec; 8(6):535-40. PubMed ID: 14760887
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sequence heterogeneity of NS5A and core proteins of hepatitis C virus and virological responses to pegylated-interferon/ribavirin combination therapy.
    El-Shamy A; Shoji I; Saito T; Watanabe H; Ide YH; Deng L; Kawata S; Hotta H
    Microbiol Immunol; 2011 Jun; 55(6):418-26. PubMed ID: 21371092
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prospective characterization of full-length hepatitis C virus NS5A quasispecies during induction and combination antiviral therapy.
    Nousbaum J; Polyak SJ; Ray SC; Sullivan DG; Larson AM; Carithers RL; Gretch DR
    J Virol; 2000 Oct; 74(19):9028-38. PubMed ID: 10982347
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutations in the interferon sensitivity-determining region (nonstructural 5A amino acid 2209-2248) in patients with hepatitis C-1b infection and correlating response to combined therapy of pegylated interferon and ribavirin.
    Yen YH; Hung CH; Hu TH; Chen CH; Wu CM; Wang JH; Lu SN; Lee CM
    Aliment Pharmacol Ther; 2008 Jan; 27(1):72-9. PubMed ID: 17973647
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutations in the NS5A gene are associated with response to interferon+ribavirin combination therapy in patients with chronic hepatitis C virus 3a infection.
    Ullah S; Rehman HU; Idrees M
    Eur J Gastroenterol Hepatol; 2013 Oct; 25(10):1146-51. PubMed ID: 23611896
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictive factors of virological non-response to interferon-ribavirin combination therapy for patients infected with hepatitis C virus of genotype 1b and high viral load.
    Akuta N; Suzuki F; Sezaki H; Suzuki Y; Hosaka T; Someya T; Kobayashi M; Saitoh S; Watahiki S; Sato J; Kobayashi M; Arase Y; Ikeda K; Kumada H
    J Med Virol; 2006 Jan; 78(1):83-90. PubMed ID: 16299715
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlation between mutations in the core and NS5A genes of hepatitis C virus genotypes 1a, 1b, 3a, 3b, 6f and the response to pegylated interferon and ribavirin combination therapy.
    Kumthip K; Pantip C; Chusri P; Thongsawat S; O'Brien A; Nelson KE; Maneekarn N
    J Viral Hepat; 2011 Apr; 18(4):e117-25. PubMed ID: 20955493
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of NS5A sequences of Hepatitis C virus genotype 1a on early viral kinetics during treatment with peginterferon- alpha 2a plus ribavirin.
    Dal Pero F; Tang KH; Gerotto M; Bortoletto G; Paulon E; Herrmann E; Zeuzem S; Alberti A; Naoumov NV
    J Infect Dis; 2007 Oct; 196(7):998-1005. PubMed ID: 17763320
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of ribavirin on the hepatitis C virus (JFH-1) and its correlation with interferon sensitivity.
    Brochot E; Duverlie G; Castelain S; Morel V; Wychowski C; Dubuisson J; François C
    Antivir Ther; 2007; 12(5):805-13. PubMed ID: 17713164
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of Hepatitis C Virus Genotype 1b Core and NS5A Mutations on Response to Peginterferon Plus Ribavirin Combination Therapy.
    Nakamoto S; Imazeki F; Arai M; Yasui S; Nakamura M; Haga Y; Sasaki R; Kanda T; Shirasawa H; Yokosuka O
    Int J Mol Sci; 2015 Sep; 16(9):21177-90. PubMed ID: 26370958
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of retreatment with interferon alone or interferon plus ribavirin on hepatitis C virus quasispecies diversification in nonresponder patients with chronic hepatitis C.
    Gerotto M; Sullivan DG; Polyak SJ; Chemello L; Cavalletto L; Pontisso P; Alberti A; Gretch DR
    J Virol; 1999 Sep; 73(9):7241-7. PubMed ID: 10438811
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quasispecies of hepatitis C virus genotype 1 and treatment outcome with peginterferon and ribavirin.
    Jardim AC; Yamasaki LH; de Queiróz AT; Bittar C; Pinho JR; Carareto CM; Rahal P; Mello IM
    Infect Genet Evol; 2009 Jul; 9(4):689-98. PubMed ID: 19063998
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NS5A(ISDR-V3) region genetic variability of Tunisian HCV-1b strains: Correlation with the response to the combined interferon/ribavirin therapy.
    Bouzgarrou N; Hassen E; Mahfoudh W; Gabbouj S; Schvoerer E; Ben Yahia A; Ben Mami N; Triki H; Chouchane L
    J Med Virol; 2009 Dec; 81(12):2021-8. PubMed ID: 19856481
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evolution of hepatitis C virus genome in chronically infected patients receiving ribavirin monotherapy.
    Querenghi F; Yu Q; Billaud G; Maertens G; Trépo C; Zoulim F
    J Viral Hepat; 2001 Mar; 8(2):120-31. PubMed ID: 11264732
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutations in the NS5A gene of hepatitis C virus subtype 1b and response to peg-IFNα-2a/RBV combination therapy in Azerbaijani patients.
    Bokharaei-Salim F; Keyvani H; Salehi-Vaziri M; Sadeghi F; Monavari SH; Mehrnoush L; Alavian SM
    Arch Virol; 2014 Nov; 159(11):2893-9. PubMed ID: 25139545
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Mutation analysis of ISDR and V3 domains of hepatitis C virus NS5A region before interferon therapy with or without ribavirin].
    Veillon P; Payan C; Gaudy C; Goudeau A; Lunel F
    Pathol Biol (Paris); 2004 Nov; 52(9):505-10. PubMed ID: 15531113
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutations in the NS5A and E2-PePHD regions of hepatitis C virus genotype 1b and response to combination therapy of interferon plus ribavirin.
    Yang SS; Lai MY; Chen DS; Chen GH; Kao JH
    Liver Int; 2003 Dec; 23(6):426-33. PubMed ID: 14986817
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of sequences of hepatitis C virus NS5A genotype 1 in HIV-coinfected patients with a null response to nitazoxanide or peg-interferon plus ribavirin.
    Sede M; Laufer N; Ojeda D; Gun A; Cahn P; Quarleri J
    Arch Virol; 2013 Sep; 158(9):1907-15. PubMed ID: 23553458
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Longitudinal analysis of the 5'UTR, E2-PePHD and NS5A-PKRBD genomic regions of hepatitis C virus genotype 1a in association with the response to peginterferon and ribavirin therapy in HIV-coinfected patients.
    Bolcic F; Laufer N; Torres C; Cassino L; Reynoso R; Quarleri J
    Antiviral Res; 2012 Aug; 95(2):72-81. PubMed ID: 22683884
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Meta-analysis of mutations in the NS5A gene and hepatitis C virus resistance to interferon therapy: uniting discordant conclusions.
    Schinkel J; Spaan WJ; Kroes AC
    Antivir Ther; 2004 Apr; 9(2):275-86. PubMed ID: 15134190
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.